search
Back to results

Safe and Healthy Schools

Primary Purpose

Sars-CoV-2 Infection, COVID-19

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
BinaxNOW Test
"Lollipop" swab
Sponsored by
University of Wisconsin, Madison
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Sars-CoV-2 Infection focused on measuring testing, diagnosis, schools

Eligibility Criteria

4 Years - undefined (Child, Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • school children ages 4-19
  • MMSD staff
  • have at least one symptom of COVID-19
  • have not had a positive COVID-19 test in the past 3 months
  • will undergo nasal PCR testing at an MMSD elementary school

Exclusion Criteria:

  • received a positive COVID-19 test in the past 3 months

Criteria for inclusion in the final study sample:

  • Aim 1. Symptomatic participants with a negative at-school BinaxNOW test and nasal PCR results who complete both the lollipop PCR and at-home BinaxNOW tests within 72 hours will be included in the final study sample.
  • Aim 2. Symptomatic participants who provide a lollipop swab that is successfully resulted.

Criteria for exclusion in the final study sample:

  • Aim 1

    • Missing nasal PCR result
    • Do not successfully complete an at-home BinaxNOW test within 72 hours of the at-school BinaxNOW test
  • Aim 2

    • Missing nasal PCR result
    • Missing lollipop PCR result

Sites / Locations

  • Community Locations

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

BinaxNOW Test + Lollipop PCR

Arm Description

If a symptomatic participant's initial at-school BinaxNOW test was positive, then their study participation is complete after providing the lollipop swab for PCR testing. If a symptomatic participant's initial at-school BinaxNOW test was negative, then they will be asked to complete an at-home BinaxNOW test approximately 24 hours later. For the at-home BinaxNOW testing, the participant will schedule a follow-up virtual visit with the study coordinator. If they are unable to complete a virtual visit, they will schedule an in-person home visit. They will also be sent home with a BinaxNOW testing kit.

Outcomes

Primary Outcome Measures

Negative Predictive Value (NPV) of BinaxNOW
The primary diagnostic outcome measure will be the negative predictive value (NPV). The NPV of BinaxNow is ~91% in symptomatic subjects. The null hypothesis is that the negative predictive value of BinaxNOW is at least 91% (which is the reported rate in symptomatic subjects after a single test) versus the alternative hypothesis that the NPV is greater than 91%.
Tabulated Results from Nasal vs Lollipop Swab-based PCR tests
The hypothesis is that the lollipop swab test will be non-inferior to the gold-standard PCR testing of nasal swabs. Concordance between the PCR test results will be evaluated by calculating the Kappa statistic which will be reported along with corresponding two-sided 95% confidence interval. The nonparametric bootstrap technique will be used to construct the confidence interval. A kappa statistic of >0.95 will be considered as sufficient to define lollipop swab test non-inferior to the gold standard PCR testing of nasal swabs.
Number of successfully completed at-home tests
Feasibility of 'at-home' BinaxNOW testing will be determined by number of successfully completed at-home tests. At-home test taking will be monitored by study team remotely (via zoom or similar).
Percent of participants who answer 'yes' when asked if lollipop swabs are more acceptable than nasal swabs
To address the acceptability of lollipop swabs vs nasal swabs, the study team will ask participants a binary question: Are lollipop swabs more acceptable to participants when compared to nasal swabs? Yes/No.

Secondary Outcome Measures

Full Information

First Posted
October 21, 2021
Last Updated
August 4, 2023
Sponsor
University of Wisconsin, Madison
search

1. Study Identification

Unique Protocol Identification Number
NCT05105789
Brief Title
Safe and Healthy Schools
Official Title
Safe and Healthy Schools
Study Type
Interventional

2. Study Status

Record Verification Date
August 2023
Overall Recruitment Status
Completed
Study Start Date
October 11, 2021 (Actual)
Primary Completion Date
May 21, 2023 (Actual)
Study Completion Date
May 21, 2023 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Wisconsin, Madison

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Device Product Not Approved or Cleared by U.S. FDA
Yes
Product Manufactured in and Exported from the U.S.
No

5. Study Description

Brief Summary
This study will target Madison Metropolitan School District (MMSD) school children ages 4-19 and staff who have not had a previous positive COVID-19 test within the past 3 months. It will enroll children and adults for 1-3 days to explore whether serial "at-home" BinaxNOW testing is feasible and non-inferior to "at school" single PCR testing for the evaluation of symptomatic individuals with a negative initial BinaxNOW. It will also explore whether lollipop swabs are more acceptable and perform as well as nasal swabs with polymerase chain reaction (PCR) testing.
Detailed Description
Study Design: This is a quantitative community-based study, conducted in the K-12 setting with school children 4-19 years old, teachers, and staff. If a participant's initial at-school BinaxNOW test is positive, then they will only complete the lollipop swab for PCR testing. They will NOT do the at-home BinaxNOW test. If a participant's initial at-school BinaxNOW test is negative, then they will complete both the lollipop swab for PCR testing AND an at-home BinaxNOW test approximately 24 hours later. If the participant is unwilling or unable to complete the at-home test, they will be presented with a lollipop swab only option. Aim 1: The investigators will test the hypothesis that serial at-home BinaxNOW testing will be feasible and non-inferior to the single at-school PCR testing program. To do this, the investigators will distribute over-the-counter BinaxNOW antigen tests to volunteer families, and create a protocol to ensure families can perform and report test results accurately to the school. Two key questions will be addressed: Is 'at-home' BinaxNOW testing feasible for families? Is serial 'at-home' BinaxNOW testing non-inferior to 'at-school' single PCR testing? Aim 2: The investigators will test the hypothesis that lollipop swabs are more acceptable to individuals and PCR testing is non-inferior to performing PCR on nasal swabs. To test this hypothesis, the investigators will work with MMSD schools to incorporate a lollipop swab for PCR at the time a symptomatic student or staff receives a nasal swab for PCR that is part of the Department of Health Services (DHS) program. Two key questions will be addressed: Are lollipop swabs more acceptable to individuals when compared to nasal swabs? Will lollipop swabs perform as well as nasal swabs with PCR-based testing? Hypotheses to be tested: Aim 1.1: "At-home" BinaxNOW testing will be feasible for families. Aim 1.2: Serial "at-home" BinaxNOW testing is non-inferior to "at school" single PCR testing. Aim 2.1: Lollipop swabs are more acceptable to individuals than nasal swabs. Aim 2.2: Lollipop swabs will perform as well as nasal swabs with PCR-based testing. Protocol Amendment 2/4/22 to expand the upper eligible age for children from 14 to 19 years and to recognize the potential supply chain limitations of BinaxNOW tests. If the study team does not have any BinaxNOW tests due to a supply shortage, the BinaxNOW procedures will be dropped and only the lollipop swab will be collected. Protocol Amendment 5/16/22 extends the study timeline and adds a lollipop swab only option.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Sars-CoV-2 Infection, COVID-19
Keywords
testing, diagnosis, schools

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
100 (Actual)

8. Arms, Groups, and Interventions

Arm Title
BinaxNOW Test + Lollipop PCR
Arm Type
Experimental
Arm Description
If a symptomatic participant's initial at-school BinaxNOW test was positive, then their study participation is complete after providing the lollipop swab for PCR testing. If a symptomatic participant's initial at-school BinaxNOW test was negative, then they will be asked to complete an at-home BinaxNOW test approximately 24 hours later. For the at-home BinaxNOW testing, the participant will schedule a follow-up virtual visit with the study coordinator. If they are unable to complete a virtual visit, they will schedule an in-person home visit. They will also be sent home with a BinaxNOW testing kit.
Intervention Type
Diagnostic Test
Intervention Name(s)
BinaxNOW Test
Other Intervention Name(s)
BinaxNOW COVID-19 Ag Card
Intervention Description
diagnostic test for SARS-CoV-2
Intervention Type
Diagnostic Test
Intervention Name(s)
"Lollipop" swab
Intervention Description
A lollipop swab, is an oral swab to collect saliva, sucked on like a lollipop for 20 seconds.
Primary Outcome Measure Information:
Title
Negative Predictive Value (NPV) of BinaxNOW
Description
The primary diagnostic outcome measure will be the negative predictive value (NPV). The NPV of BinaxNow is ~91% in symptomatic subjects. The null hypothesis is that the negative predictive value of BinaxNOW is at least 91% (which is the reported rate in symptomatic subjects after a single test) versus the alternative hypothesis that the NPV is greater than 91%.
Time Frame
up to 2 days
Title
Tabulated Results from Nasal vs Lollipop Swab-based PCR tests
Description
The hypothesis is that the lollipop swab test will be non-inferior to the gold-standard PCR testing of nasal swabs. Concordance between the PCR test results will be evaluated by calculating the Kappa statistic which will be reported along with corresponding two-sided 95% confidence interval. The nonparametric bootstrap technique will be used to construct the confidence interval. A kappa statistic of >0.95 will be considered as sufficient to define lollipop swab test non-inferior to the gold standard PCR testing of nasal swabs.
Time Frame
up to 1 day
Title
Number of successfully completed at-home tests
Description
Feasibility of 'at-home' BinaxNOW testing will be determined by number of successfully completed at-home tests. At-home test taking will be monitored by study team remotely (via zoom or similar).
Time Frame
up to 24 hours
Title
Percent of participants who answer 'yes' when asked if lollipop swabs are more acceptable than nasal swabs
Description
To address the acceptability of lollipop swabs vs nasal swabs, the study team will ask participants a binary question: Are lollipop swabs more acceptable to participants when compared to nasal swabs? Yes/No.
Time Frame
up to 1 day

10. Eligibility

Sex
All
Minimum Age & Unit of Time
4 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: school children ages 4-19 MMSD staff have at least one symptom of COVID-19 have not had a positive COVID-19 test in the past 3 months will undergo nasal PCR testing at an MMSD elementary school Exclusion Criteria: received a positive COVID-19 test in the past 3 months Criteria for inclusion in the final study sample: Aim 1. Symptomatic participants with a negative at-school BinaxNOW test and nasal PCR results who complete both the lollipop PCR and at-home BinaxNOW tests within 72 hours will be included in the final study sample. Aim 2. Symptomatic participants who provide a lollipop swab that is successfully resulted. Criteria for exclusion in the final study sample: Aim 1 Missing nasal PCR result Do not successfully complete an at-home BinaxNOW test within 72 hours of the at-school BinaxNOW test Aim 2 Missing nasal PCR result Missing lollipop PCR result
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ellen R Wald, MD
Organizational Affiliation
University of Wisconsin, Madison
Official's Role
Principal Investigator
Facility Information:
Facility Name
Community Locations
City
Madison
State/Province
Wisconsin
ZIP/Postal Code
53705
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Safe and Healthy Schools

We'll reach out to this number within 24 hrs